Samsung has unveiled the Galaxy Ring 2, and its headline feature is one the wearable technology industry has pursued for over a decade: continuous, non-invasive blood glucose monitoring without finger pricks or implanted sensors. The device was announced on Saturday, June 7, 2026, and represents what health tech analysts are calling the most significant advance in consumer health wearables since the widespread adoption of optical heart rate monitoring.
How It Works
The Galaxy Ring 2 combines two optical sensing technologies to estimate blood glucose levels continuously throughout the day. Photoplethysmography (PPG) sensors, which are already standard in smartwatches for heart rate and blood oxygen monitoring, work alongside new mid-infrared optical sensors embedded in the ring. The mid-infrared component is critical because glucose molecules absorb infrared light at specific wavelengths, allowing the sensor to detect subtle changes in the optical properties of blood flowing through the finger.
Samsung has not described the system as a certified medical glucose meter replacement, instead positioning it as a continuous trend monitor. The company presented clinical validation data in its announcement materials showing the device achieves accuracy within ranges comparable to consumer continuous glucose monitors for most reading conditions, though performance degrades during intense physical activity and at temperature extremes.
Regulatory Status
The Galaxy Ring 2 has received regulatory clearance for glucose trend monitoring in South Korea, Samsung confirmed. U.S. FDA clearance is listed as pending, meaning the device will initially ship in South Korea and select Asian markets before a U.S. launch timeline is determined. The distinction between "trend monitoring" and "diagnostic measurement" is significant from a regulatory standpoint: trend devices have a lower evidentiary bar than CGMs intended to guide insulin dosing decisions.
Coverage from The Verge examined Samsung's presented accuracy methodology carefully, noting that the company is promoting correlation with lab reference values rather than absolute accuracy comparisons with FDA-cleared CGMs like Dexcom or Abbott Libre systems. Independent validation studies will be the true test of whether the Galaxy Ring 2's glucose feature holds up under real-world conditions across diverse user populations.
Market Context
The race to non-invasive glucose monitoring has claimed several high-profile casualties over the years. Apple has reportedly been developing similar optical glucose technology for the Apple Watch for several years without a commercial product. Alphabet-backed Verily and numerous venture-backed startups have also pursued the capability with limited public success. Samsung's announcement, backed by regulatory clearance in one market, positions it as the first major consumer electronics company to bring non-invasive glucose trend monitoring to a shipping product.
For the estimated 500 million people worldwide living with diabetes, as well as the much larger population managing prediabetes or metabolic health, a comfortable, always-on glucose trend sensor embedded in a ring form factor offers significant potential quality-of-life improvements over current solutions, which require either implanted sensors, finger-stick meters, or expensive CGM systems.
Why It Matters
If Samsung's clinical accuracy data holds up under independent scrutiny, the Galaxy Ring 2 will represent a genuine inflection point for consumer health technology. Non-invasive glucose monitoring has been widely considered the most important unsolved problem in wearable health sensing for a decade. A validated, broadly available solution would accelerate adoption of continuous metabolic monitoring across both diagnosed diabetics and the wellness-focused general population. It would also significantly raise the bar for competitors in the smart ring space, including Oura and competing medical wearable makers, to match the Galaxy Ring 2 feature set. The broader implication is that consumer-grade hardware is increasingly capable of capabilities once reserved for medical-grade clinical devices.